セッション詳細
[O6]Oral Presentations 6
2025年3月18日(火) 15:15 〜 16:25
神戸国際会議場 メインホール(1F)
Chair: 山本 一彦 (理化学研究所 生命医科学研究センター)
Presentations 4 - 8 in this session are candidates for the Oral Presentation Award for Early-career Researchers
[O6-01]Optimizing CRISPR precision for the production of knockout mice and monkeys with a predictable and homogeneous mutation in the founder generation
Khanui Lkhagvadorj1, Eiichi Okamura1, Hideaki Tsuchiya1, Chizuru Iwatani1, Yasushi Itoh2, *Masatsugu Ema1 (1. Research Center for Animal Life Science, Shiga University of Medical Science (Japan), 2. Division of Pathogenesis and Disease Regulation, Shiga University of Medical Science (Japan))
[O6-02]Vaccine development against invasive Salmonella
*Toshio Kodama1, Pham Thi Hoan1, Sarunporn Tandhavanant1, Hirataka Hiyoshi 1 (1. Institute of Tropical Medicine, Nagasaki University (Japan))
[O6-03]Helicobacter pylori関連疾患のオミックス解析
Omics analysis of Helicobacter pylori-related diseases
*Koichi Matsuda1 (1. Institute of Medical Science, The University of Tokyo (Japan))
[O6-04E]Blood DNA virome associates with autoimmune diseases and COVID-19
*Noah Sasa1,3, Shohei Kojima2, Rie Koide2, Rei Watanabe1,4, Yuumi Nakamura1, Shinichi Imafuku5, Yayoi Tada6, Shinichi Sato3, Masatoshi Jinnin7, Tatsuyoshi Kawamura8, Shinji Shimada8, Shigetoshi Sano9, Manabu Fujimoto1, Akimichi Morita10, Atsushi Kumanogoh1, Nicholas F. Parrish2, Yukinori Okada1,3 (1. Osaka University (Japan), 2. RIKEN Center for Integrative Medical Sciences (Japan), 3. The University of Tokyo (Japan), 4. Juntendo University (Japan), 5. Fukuoka University (Japan), 6. Teikyo University (Japan), 7. Wakayama Medical University (Japan), 8. University of Yamanashi (Japan), 9. Kochi University (Japan), 10. Nagoya City University (Japan))
[O6-05E]新型コロナワクチンをめぐる人々の話題・関心の変化 -１億超の大規模Twitterデータを読み解く -
Evolution of Public Opinion on COVID-19 Vaccination in Japan: Large-Scale Twitter Data Analysis
*Ryota Kobayashi1 (1. The University of Tokyo (Japan))
[O6-06E]Vaccine design inducing protective cellular immunity against Plasmodium falciparum across strain and HLA polymorphisms
*HUAI CHUANG1,2, Agnieszka Gromadka8, Vegard Børve Sørdal8, Marius Gheorghe8, Wataru Kagaya1,6, Shusaku Mizukami1,5, Shinya Miyazaki1,2, Ayako Hyuga1,3, Shara Bakytbek1,3, Farzaneh Valanezhad1,3, Shin-Ichi Inoue1,4, Satoshi Kaneko1,6, Sebastian Kapell1,7, Ioannis Vardaxis8, Alexandru Odainic8, Matheus Ferraz8, Daiki Mori9, Daiki Miura9, Yuki Tanaka9, Shinjiro Hamano1,3, Kaidre Bendjama8, Kazuhide Onoguchi9, Osamu Kaneko1,2 (1. Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance, Nagasaki Univ. (Japan), 2. Dept. of Protozool., Inst. of Trop. Med. (NEKKEN), Nagasaki Univ. (Japan), 3. Dept. Parasitol., Inst. Trop. Med. (NEKKEN), Nagasaki Univ. (Japan), 4. Dept. of Immunol., Grad. Sch. of Biomed. Sci., Nagasaki Univ. (Japan), 5. Dept. of Immun. Regul., Inst. of Trop. Med. (NEKKEN), Nagasaki Univ. (Japan), 6. Dept. of Eco-epidemiol., Inst. of Trop. Med. (NEKKEN), Nagasaki Univ. (Japan), 7. Dept. of Vacc. Inform., Inst. of Trop. Med. (NEKKEN), Nagasaki Univ. (Japan), 8. NEC Oncoimmunity AS, Oslo (Norway), 9. NEC Corporation (Japan))
[O6-07E]Optimization of orthoflavivirus antigen synthesis for vaccine development
*Koshiro Tabata1, Gabriel Gonzalez1, Yukari Itakura1, Shinji Saito1, Hirofumi Sawa1 (1. Institute for Vaccine Research and Development, Hokkaido University (Japan))